Title: Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis
Version: 3 Date: 03 Jun 2023
Reviewer:  Anuraag Jena
Reviewer's report:
Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis
The authors have done a great work in summarizing the evidence in NMA. There are some
queries that they could explain.
The top 3 drugs in UC  in the network analysis should be mentioned in the abstract. This should
be in terms of both efficacy and safety.
Were the Phase 2 studies also clubbed with Phase 3 RCT in the included studies? As dosages
of newer drugs might be a confounding factor. Phase 3 trials will have established dosage with
maximum efficacy.
Were the outcomes similar in mild versus mod-severe UC?
Were the outcomes different in induction and maintenance RCTs?
What about the outcomes in patients with prior exposure to TNF antagonists?
Did the authors take out data for serious infections in safety outcomes?
What were the concomitant medications in the included RCTs?
Title: Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis
Version: 3 Date: 03 Jun 2023
Reviewer:  Anuraag Jena
Reviewer's report:
Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis
The authors have done a great work in summarizing the evidence in NMA. There are some
queries that they could explain.
The top 3 drugs in UC  in the network analysis should be mentioned in the abstract. This should
be in terms of both efficacy and safety.
Were the Phase 2 studies also clubbed with Phase 3 RCT in the included studies? As dosages
of newer drugs might be a confounding factor. Phase 3 trials will have established dosage with
maximum efficacy.
Were the outcomes similar in mild versus mod-severe UC?
Were the outcomes different in induction and maintenance RCTs?
What about the outcomes in patients with prior exposure to TNF antagonists?
Did the authors take out data for serious infections in safety outcomes?
What were the concomitant medications in the included RCTs?
Please review this paper.
user
Title: Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis
Version: 3 Date: 03 Jun 2023
Reviewer:  Anuraag Jena
Reviewer's report:
Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis
The authors have done a great work in summarizing the evidence in NMA. There are some
queries that they could explain.
The top 3 drugs in UC  in the network analysis should be mentioned in the abstract. This should
be in terms of both efficacy and safety.
Were the Phase 2 studies also clubbed with Phase 3 RCT in the included studies? As dosages
of newer drugs might be a confounding factor. Phase 3 trials will have established dosage with
maximum efficacy.
Were the outcomes similar in mild versus mod-severe UC?
Were the outcomes different in induction and maintenance RCTs?
What about the outcomes in patients with prior exposure to TNF antagonists?
Did the authors take out data for serious infections in safety outcomes?
What were the concomitant medications in the included RCTs?
assistant